The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Biology of RANK, RANKL, and osteoprotegerin
Open accessAbstract
The discovery of the receptor activator of nuclear factor-kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) system and its role in the regulation of bone resorption exemplifies how both serendipity and a logic-based approach can identify factors that regulate cell function. Before this discovery in the mid to late 1990s, it had long been recognized that osteoclast formation was regulated by factors expressed by osteoblast/stromal cells, but it had not been anticipated that members of the tumor necrosis factor superfamily of ligands and receptors would be involved or that the factors involved would have extensive functions beyond bone remodeling. RANKL/RANK signaling regulates the formation of multinucleated osteoclasts from their precursors as well as their activation and survival in normal bone remodeling and in a variety of pathologic conditions. OPG protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from binding to its receptor, RANK. Thus, RANKL/OPG ratio is an important determinant of bone mass and skeletal integrity. Genetic studies in mice indicate that RANKL/RANK signaling is also required for lymph node formation and mammary gland lactational hyperplasia, and that OPG also protects arteries from medial calcification. Thus, these tumor necrosis factor superfamily members have important functions outside bone. Although our understanding of the mechanisms whereby they regulate osteoclast formation has advanced rapidly during the past 10 years, many questions remain about their roles in health and disease. Here we review our current understanding of the role of the RANKL/RANK/OPG system in bone and other tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,701
Reaching a Genetic and Molecular Understanding of Skeletal Development
Karsenty, G., & Wagner, E. F. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00157-0 · Cited by 1,601
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
Lomaga, M. A., Yeh, W.-C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S., et al. (1999) · Genes & Development · doi:10.1101/gad.13.8.1015 · Cited by 1,267
RANKL–RANK signaling in osteoclastogenesis and bone disease
Wada, T., Nakashima, T., Hiroshi, N., & Penninger, J. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.11.007 · Cited by 1,212
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Role of osteoblasts in hormonal control of bone resorption—A hypothesis
Rodan, G. A., & Martin, T. J. (1981) · Calcified Tissue International · doi:10.1007/bf02409454 · Cited by 982
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis
Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., Iwata, T., Ohnishi, H., Matozaki, T., Kodama, T., et al. (2004) · Nature · doi:10.1038/nature02444 · Cited by 828
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells
Kollet, O., Dar, A., Shivtiel, S., Kalinkovich, A., Lapid, K., Sztainberg, Y., Tesio, M., Samstein, R. M., Goichberg, P., Spiegel, A., et al. (2006) · Nature Medicine · doi:10.1038/nm1417 · Cited by 775
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β
Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. (2002) · Nature · doi:10.1038/416744a · Cited by 717
Osteoclast-derived activity in the coupling of bone formation to resorption
Martin, T. J., & Sims, N. A. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.004 · Cited by 659
Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K., Nakamura, K., Katsuki, M., Yamamoto, T., et al. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00265.x · Cited by 635
NFAT and Osterix cooperatively regulate bone formation
Koga, T., Matsui, Y., Asagiri, M., Kodama, T., de Crombrugghe, B., Nakashima, K., & Takayanagi, H. (2005) · Nature Medicine · doi:10.1038/nm1270 · Cited by 490
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
Hughes, A. E., Ralston, S. H., Marken, J., Bell, C., MacPherson, H., Wallace, R. G. H., van Hul, W., Whyte, M. P., Nakatsuka, K., Hovy, L., et al. (2000) · Nature Genetics · doi:10.1038/71667 · Cited by 481
Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Collin-Osdoby, P. (2004) · Circulation Research · doi:10.1161/01.res.0000149165.99974.12 · Cited by 473
Osteoprotegerin Deficiency and Juvenile Paget's Disease
Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H., & Mumm, S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013096 · Cited by 445
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., Vargo-Gogola, T. C., Begtrup, J. L., Peterson, T. E., Fingleton, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.013 · Cited by 393
Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304 · cited 1×
“Furthermore, the absence of OPG in OPG/apolipoprotein E double knockout mice accelerates the calcific atherosclerosis that develops in apolipoprotein E knockout mice, suggesting that OPG protects against this complication of atherosclerosis [ 33 ].”
BackgroundDaily and Cyclic Parathyroid Hormone in Women Receiving Alendronate
Cosman, F., Nieves, J., Zion, M., Woelfert, L., Luckey, M., & Lindsay, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050157 · Cited by 250
Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M., & Tanaka, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606656200 · Cited by 236
Cundy, T. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.18.2119 · Cited by 228
Chen, G., Sircar, K., Aprikian, A., Potti, A., Goltzman, D., & Rabbani, S. A. (2006) · Cancer · doi:10.1002/cncr.21978 · Cited by 226
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Ikeda, T., Kasai, M., Utsuyama, M., & Hirokawa, K. (2001) · Endocrinology · doi:10.1210/endo.142.4.8070 · Cited by 215
Li, P., Schwarz, E. M., O'Keefe, R. J., Ma, L., Looney, R. J., Ritchlin, C. T., Boyce, B. F., & Xing, L. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11419 · Cited by 205
Self-citationYao, Z., Li, P., Zhang, Q., Schwarz, E. M., Keng, P., Arbini, A., Boyce, B. F., & Xing, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512624200 · Cited by 192
Self-citationMechanisms of Disease: the link between RANKL and arthritic bone disease
Schett, G., Hayer, S., Zwerina, J., Redlich, K., & Smolen, J. S. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0036 · Cited by 191
The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis
Wada, T., Nakashima, T., Oliveira-dos-Santos, A. J., Gasser, J., Hara, H., Schett, G., & Penninger, J. M. (2005) · Nature Medicine · doi:10.1038/nm1203 · Cited by 182
Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation
ÉBAUD, D. T., Krieg, M., Berguer, D. G., Jacquet, A. F., Goy, J., & BURCKHARDT, P. (1996) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1996.00170.x · Cited by 154
Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2
Kim, N., Kim, H.-J., Koo, B., Kwon, M.-C., Kim, Y.-W., Cho, Y., Yokota, Y., Penninger, J. M., & Kong, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1002-1013.2006 · Cited by 116
Ma, Y. L., Bryant, H. U., Zeng, Q., Schmidt, A., Hoover, J. L., Cole, H. W., Yao, W., Jee, W. S. S., & Sato, M. (2003) · Endocrinology · doi:10.1210/en.2002-221061 · Cited by 91
Osteoprotegerin, the bone protector, is a surprising target for β-catenin signaling
Boyce, B. F., Xing, L., & Chen, D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.011 · Cited by 56
Self-citationMalignant Autosomal Recessive Osteopetrosis Caused by Spontaneous Mutation of Murine Rank
Kapur, R. P., Yao, Z., Iida, M. H., Clarke, C. M., Doggett, B., Xing, L., & Boyce, B. F. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040713 · Cited by 39
Self-citationMMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Westendorf, J. J., & Hoeppner, L. H. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2006.12.003 · Cited by 39
Cited by
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844
Self-citationKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Osteoimmunomodulation for the development of advanced bone biomaterials
Chen, Z., Klein, T., Murray, R. Z., Crawford, R., Chang, J., Wu, C., & Xiao, Y. (2016) · Materials Today · doi:10.1016/j.mattod.2015.11.004 · Cited by 730
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
Periodontitis is an inflammatory disease of oxidative stress: We should treat it that way
Sczepanik, F. S. C., Grossi, M. L., Casati, M., Goldberg, M., Glogauer, M., Fine, N., & Tenenbaum, H. C. (2020) · Periodontology 2000 · doi:10.1111/prd.12342 · Cited by 679
Metadata
- Authors
- Boyce, B. F., & Xing, L.
- Venue
- Arthritis Research & Therapy
- Published
- 2007
- Volume
- 9
- Issue
- Suppl 1
- Pages
- S1
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2046675807
- Cited by
- 957
- References
- 46
- Type
- conference abstract
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.